RajeevKumarMD

Neurology • Englewood, CO

Medical Director, Movement Disorders Specialist

Join to view full profile

Dr. Kumar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kumar's full profile

Already have an account?

Office
701 E. Hampden Ave
Suite 510
Englewood, CO 80013
Phone+1 303-357-5455

Fax+1 303-357-5459

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Residency, Neurology, 1992 - 1995
Mayo Clinic College of Medicine and Science (Rochester)Internship, Internal Medicine, 1991 - 1992
University Saskatchewan Royal HospitalClass of 1991

Certifications & Licensure

CO State Medical License 1998 - 2025
MN State Medical License 1992 - 2009
TX State Medical License 2005 - 2009
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013

Clinical Trials

Neurobiological Predictors of Huntington's Disease (PREDICT-HD) Start of enrollment: 2002 Aug 01
Active, not recruiting
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort Start of enrollment: 2012 Jul 01
Recruiting
A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation Start of enrollment: 2013 Sep 01
Terminated
Phase 2
A Study to Examine APL-130277 in Patients With Parkinson's Disease Start of enrollment: 2014 Aug 31
Completed
Phase 2
Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation Start of enrollment: 2017 May 11
Completed
Phase 1, Phase 2
Fixed-Dose Trial in Early Parkinson's Disease (PD) Start of enrollment: 2019 Dec 13
Active, not recruiting
Phase 3
Roles: Contact
Open-label Trial in Parkinson's Disease (PD) Start of enrollment: 2021 Feb 24
Enrolling by invitation
Phase 3
Roles: Contact
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations Start of enrollment: 2020 Oct 27
Completed
Phase 3
Roles: Contact
A Study of TAK-071 in People With Parkinson Disease Start of enrollment: 2020 Oct 21
Completed
Phase 2
Roles: Principal Investigator
HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States Start of enrollment: 2020 Jun 21
Completed
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Underutilization of Injectable Parkinson's Disease Medication: An Analysis of Neurologist and Patient Perspectives.
Gianni Solis, Jordan Patierno, Josh Rossol, Rajeev Kumar
Movement Disorders Clinical Practice. 2024-12-01
25 citations
Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies.
Christopher H Gibbons, Todd Levine, Charles Adler, Bailey Bellaire, Ningshan Wang
JAMA. 2024-04-16
Apomorphine titration with and without anti-emetic pretreatment in patients with Parkinson's disease experiencing OFF episodes: A modified Delphi panel.
Stuart H Isaacson, Richard Dewey, Robert A Hauser, Daniel Kremens, Rajeev Kumar
Clinical Parkinsonism & Related Disorders. 2024-01-01

Press Mentions

CenExel Clinical Research Acquires Rocky Mountain Movement Disorders CenterJanuary 11th, 2022
Assessment of Myocardial Sympathetic Innervation with 18f-FDOPA-PET/CT in Patients with Autonomic Dysfunction: Feasibility Study in IPD PatientsJanuary 10th, 2021
Potential of Graphene-Based Materials to Combat COVID-19: Properties, Perspectives and ProspectsOctober 21st, 2020
Join now to see all

Professional Memberships